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Abstract
Background & Aims: In the province of Cadiz (Spain), the adjusted mortality rate for gastric cancer in the coastal town 
of Barbate is 10/100.000 inhabitants, whereas in the inland town of Ubrique, the rate is twice as high. The rate of 
Helicobacter pylori (H. pylori) infection (H. pylori antibodies) in the normal population was 54% in Ubrique, but only 32% 
in Barbate. In the two decades since its original discovery, p53 has found a singularly prominent place in our 
understanding of human gastric cancer and H. pylori cause accumulation of reactive oxygen species in the mucosa 
compartment. This study was designed to compare serum levels of p53 in a population characterized by high mortality 
due to stomach cancer and a high prevalence of H. pylori infection and another population in which mortality from this 
cause and the prevalence of H. pylori infection are low.
Materials and methods: 319 subjects from the low mortality population and 308 from the high mortality population 
were studied, as were 71 patients with stomach cancer. We measured serum immunoglobulin G antibody to H. pylori 
and serum mutant p53 protein and ceruloplasmin.
Results: The difference between the two populations in the prevalence of H. pylori infection was significant (p < 0.001). 
Of the seropositive, 81% had elevated values of mutant p53, in comparison with 11% of the seronegative (p < 0.0001). 
Serum concentration of ceruloplasmin was significantly higher in seropositive with elevated mutant p53 protein than 
in seronegative with normal levels of p53 (p < 0.05).
Conclusions: There is a significant association between infection with H. pylori, elevated titers of H. pylori antibodies, 
and positivity for serum mutant p53 protein. Such information can significantly increase our basic knowledge in 
molecular pathology of gastric cancer and protection against H. pylori infection.
Introduction
Mortality due to gastric cancer in Spain has decreased
markedly since the period from 1960 to 1965, but remains
high in some mountain locations [1]. In the southern
Atlantic province of Cadiz, coastal towns such as Barbate
have an adjusted mortality rate of 10/100.000 inhabitants,
whereas towns such as Ubrique, located in the mountain-
ous region 30 kilometers inland, have an adjusted mortal-
ity rate of 20/100.000 [2]. An earlier study found that the
rate of Helicobacter pylori infection (determined by mea-
suring serum H. pylori IgG antibodies) in the normal
population was 54% in Ubrique, but only 32% in Barbate,
where the mortality rate for stomach cancer is lower.
Mean antibody titers are also higher in the area with the
higher mortality rate [2].
H. pylori, originally under the genus Campylobacter [3],
is a ubiquitous bacterial pathogen that infects more than
50% of the world's population. H. pylori was first cultured
in vitro, and shown to be associated with gastritis and
peptic ulcers, by Marshall and Warren [4]. H. pylori infec-
tion in untreated subjects is usually lifelong, and the
ongoing chronic infection can to be an etiological agent
of chronic gastritis, peptic ulcer disease and carcinoma
[5]. Chronic infection with H. pylori affects approxi-
mately half the world and results in malignancy in a small
subset of this population. Although the frequency of
infection in developed nations is falling with a resultant
decline in H. pylori-associated peptic ulcer disease, gas-
tric cancer remains the second major cause of cancer
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death worldwide, with H. pylori infection being a major
attributable factor in the development of gastric cancer
[6]. Research into the relationship between the two is
ongoing, however, suggested that between 35 and 55% of
all gastric cancers may be related to H. pylori infection
[7].
Since 1994, the International Agency for Research on
Cancer (IARC) designated H. pylori as a class I human
carcinogen, it now is well accepted that gastric infection
by H. pylori is a risk factor for development of gastric
cancer [8]. Although the precise pathogenetic role of H.
pylori  in gastric carcinogenesis remains unclear, it has
been clarified that this organism contributes to modifica-
tions in epithelial cell proliferation, which may be the ini-
tiating event in a cascade culminating in the development
of gastric cancer [9], but it is not known whether the
increased risk is due to the presence of mutant p53 gener-
ated by chronic gastritis or to a direct action of the bacte-
ria on the p53 oncogene [10,11].
T h e  p 5 3  g e n e  m u t a t i o n  i s  a s s o c i a t e d  w i t h  a p p r o x i -
mately 70% of tumors of different orignis [12,13]. p53
gene serves as a "gatekeeper of the cell", for its role in pre-
venting the accumulation of genetic alterations through
the regulation of critical checkpoints between the end of
G1 and the beginning of S to redirect cells with a muta-
tion in the genome toward apoptosis or programmed cell
death. This key oncogene thus prevents the perpetuation
of a defective genome and the development of a cancer
[14].
Several recent studies have been published on the pres-
ence of p53 in patients with H. pylori infection, stomach
cancer, or both. However, the conclusions are contradic-
tory, and it has been difficult to develop a single coherent
hypothesis that can account for all findings communi-
cated to date [15]. Palli et al [16] found p53 mutants in 33
of 105 cases of gastric cancer and Domek et al [17]
worked with the hypothesis that tumorigenesis involves
deregulation of cell proliferation and apoptosis. These
researchers investigated cell proliferation and apoptosis
in the gastric epithelium of children infected with H.
pylori, and found that the apoptotic index was signifi-
cantly higher in patients with H. pylori gastritis than in
patients with secondary gastritis or healthy control sub-
jects. They also reported that apoptosis decreased when
the bacterial infection was eradicated. Wu et al, reported
the existence of different pathways of gastric carcinogen-
esis in different histological subtypes of gastric cancer
and its progression, in which H. pylori infection can play
an important role [18]. Hibi et al, concluded that persis-
tent H. pylori infection caused gastritis, with degenera-
tion and regeneration of the epithelium that increased
cell proliferation and the accumulation of p53 [19]. This
in turn increased instability of the gene, as reflected by
the development of carcinoma, using immunohistochem-
ical methods to investigate p53 expression, and con-
cluded that expression is associated with
histopathological phenotypes, and that genetic altera-
tions may not be affected by H. pylori infection [20].
Chang et al, noted the possibility that H. pylori infection
and mutation of the tumor suppressor gene p53 may be
significantly related with the process of gastric carcino-
genesis in well differentiated and moderately well differ-
entiated carcinomas [21]. However, Hongyo et al, claimed
that  H. pylori infection was more common in patients
without any mutation in p53 [22].
The development of an enzyme-linked immunosorbent
assay (ELISA) for mutant p53 protein makes it possible to
determine most mutant p53 proteins in humans and
other mammals [23]. This test has been used to deter-
mine mutant p53 protein in the serum of apparently
healthy persons with H. pylori infection, detected as the
presence of antibodies to specific IgG [24], beacuse most
patients infected with H. pylori produce an easily identi-
fied systemic humoral immune responde, composed pri-
marily of IgG. Circulating H. pylori antibodies persist at
constant levels for years during infection.
Mutant p53 proteins have a half-life of approximately
24 h, whereas normal proteins have a half-life of about 20
min. It is this prolonged half-life which leads to the accu-
mulation of detectable amounts of p53 protein [25].
Reactive oxygen species (ROS) are a group of highly
reactive oxidative molecules implicated in the aging pro-
cess, in several chronic inflammatory disorders, and in
carcinogenic pathways in different epithelial districts
[26]. An increase in cell ROS, be it due to overproduction
and/or scavenging inability, may result in severe damage
to various cell components, including membranes, mito-
chondria, and nuclear as well as mitochondrial DNA [27].
Ceruloplasmin (CP) is a 132 kd cuproprotein which,
together with transferrin, provides the majority of anti-
oxidant capacity in serum. Cp is a serum ferroxidase that
contains greater than 95% of the copper found in plasma.
This protein is a member of the multicopper oxidase fam-
ily, an evolutionarily conserved group of proteins that uti-
lize copper to couple substrate oxidation with the four-
electron reduction of oxygen to water. Despite the need
for copper in ceruloplasmin function, this protein plays
no essential role in the transport or metabolism of this
metal [28,29].
I n  t h i s  s t u d y ,  w e  s o u g h t  t o  c o m p a r e  t h e  r e l a t i o n
between serum levels of mutant p53 protein and H. pylori
infection in two populations of similar socioeconomic
status, but with very different mortality rates for gastric
cancer. A second objective was examine indirectly by
measuring the serum concentration of the antioxidant
ceruloplasmin in patients with evidence of H. pylori
infection. Serum levels of ceruloplasmin usually vary
inversely with serum nitrite levels [30-32].Lopez-Saez et al. Journal of Experimental & Clinical Cancer Research 2010, 29:65
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Materials and methods
Type of study
This was a comparative, cross-sectional, case-control
study of two populations with different rates of mortality
from gastric cancer. This study has been ongoing since
March 2002 to October 2005. Serum ceruloplasmin levels
w e r e  a l s o  c o m p a r e d  i n  p a t i e n t s  w i t h  a n d  w i t h o u t  H.
pylori infection, and in patients with and without mutant
forms of p53. The investigators did not know whether the
subject was positive or negative for H. pylori antibodies
when they tested p53 status. For purposes of comparison,
serum levels of H. pylori antibodies and p53 status were
also determined in 71 patients with gastric cancer.
If  H. pylori infection is related with cancer, the null
hypothesis was that any variation or difference in sero-
positivity for the bacterium between the populations with
high and low mortality rates due to gastric cancer is due
to chance. The alternative hypothesis was that variations
or differences in seropositivity between the two popula-
tions suggests that seropositivity for H. pylori infection is
related with the rate of mortality from gastric cancer.
Ceruloplasmin, an organic antioxidant, is a marker for
the presence of free radicals. We measured serum con-
centrations of ceruloplasmin and looked for correlations
of these values with serum H. pylori antibody titers and
p53 levels.
The objective of this study was to compare serum p53
v a l u e s  i n  a  p o p u l a t i o n  c h a r a c t e r i z e d  b y  a  h i g h  r a t e  o f
mortality due to gastric cancer and a high prevalence of
H. pylori infection and a population with a low rate of
mortality from this cause and a low prevalence of H.
pylori seropositivity.
Study populations
The population comprised inhabitants of two towns
located 30 kilometers apart in the province of Cadiz
(southern Spain), without prior treatment of H. pylori or
who had recent eradication of H. pylori at least 8 weeks
before were recruited. Although the socioeconomic level
of the two towns is similar, Barbate is located on the
Atlantic coast, whereas Ubrique is located in a mountain-
ous inland area. We conducted a nutritional analysis and
questionnaire survey for socioeconomic status in order to
compare other risk factors that might influence H. pylori
infection between groups. No significant differences in
the nutritional factors or socioeconomic status, such as
Hollingshead index, type of house, number of siblings,
and crowding index, were found between the groups.
Participants were permanent residents of these towns
who were healthy and asymptomatic at the time of the
study. Men and women aged 18 years and over were
included.
The control group consisted in patients diagnosed with
histologically confirmed gastric cancer, at the Depart-
ments of Internal Medicine, Medical Oncology and Sur-
gery, of University Hospital Puerto Real from Cadiz. The
median age of patients was 59 years (range: 33-85 years)
and 57.5% of the patients in the series were male. Surgical
specimens of 71 formalin fixed paraffin embedded gastric
cancer with adjacent non-involved normal gastric
mucosa were obtained from Pathology Department from
our Hospital. Presence of tumor in the sections was con-
firmed by hematoxylin and eosin staining, and histologic
typing of the tumors was performed according to both
Lauren classification and WHO guidelines [33]. Speci-
mens were examined by two independet experienced
pathologists who also evaluated haematoxylin-eosin
(H&E) and Giemsa stained slides for the presence of H.
pylori.
Gastric cancers were classified according to the WHO
classification as well differentiaded (n = 21), moderately
differentiated (n = 25), poorly differentiated (n = 13), and
signet ring cell carcinomas (n = 12). Evaluation of tumor
stage was performed according to the criteria of the
International Union Against Cancer (UICC) [34].
Subjects with a history of gastric surgery, dyspepsia,
duodenal ulcer, gastric ulcer, malignancy, positive status
for human immunodeficiency virus and/or hepatitis B,
active gastrointestinal bleeding, or use of steroids or
immunosuppressive drugs, H2 receptor blockers, antibi-
otics, bismuth compounds, or proton pump inhibitors or
taking drugs interfering with free radical production
(including vitamins C, A, and E, selenium and zinc) or
similar nonprescription, were excluded. Were also
excluded if they had had any disease for which reliable
clinical information was not available, or if blood samples
could not be obtained. Not more than two members of
the same family were included.
Sampling procedure
We studied a total of 627 subjects: 308 from Barbate and
319 from Ubrique. Their ages ranged from 18 to 85
(median 55) years. For statistical analysis, were divided
into 3 age groups; younger group (18-40 years; n = 101,
median age = 29), middle-aged group (41-60 years, n =
197, median age = 53) and older group (≥ 61 years, n =
119, median age = 76). Sampling was random, and was
stratified for these three age subgroups. Participants in
this population study were visited at their home. All eligi-
ble subjects gave their informed consent for participation
in this study and carried out according to the Good Clini-
cal Practice guidelines and Helsinki Declaration.
Variables
As quantitative variables we recorded serum level of H.
pylori  IgG-specific antibody, expressed as IU/L [2,35],
serum level of p53, expressed as ng/mL, and serum con-
centration of ceruloplasmin, expressed as mg/L [36]. As a
nominal variable we recorded whether the subject was a
resident of Barbate or Ubrique. As a dichotomous vari-Lopez-Saez et al. Journal of Experimental & Clinical Cancer Research 2010, 29:65
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able we used seropositivity/seronegativity for H. pylori,
with a cut-off value of 51 IU/L.
A blood sample of 10 mL was obtained by venipunc-
ture, and the serum was separated and stored at -80°C
until analysis. Serum concentration of H. pylori IgG anti-
bodies was measured with the Biolab Malakit (Wavre,
Belgium) using an enzyme-linked immunosorbent assay
(ELISA). In using this system, manufacturer's instruc-
tions were followed. H. pylori infection was defined as a
positive ELISA result. The ELISA for serum p53 was from
Oncogene Research (Calbiochem, Cambridge, MA,
USA), that exclusively detected the mutant p53 protein,
to eliminate a possibility of cross-reaction with other pro-
teins, especially various inflammation-related products.
This assay uses a mouse monoclonal antibody and a rab-
bit polyclonal antibody; the former reacts with an epitope
located between amino acids 155 and 214 of the p53 pro-
tein, and binds exclusively to the epitope exposed on the
mutant protein, but not on the wild-type protein. There-
fore the assay is highly selective. All samples and stan-
dards were assayed in duplicate. H. pylori IgG and mutant
p53 were quantified by extrapolating the average optic
density for each set of duplicates on a standard curve
obtained with known concentrations of purified H. pylori
antibodies and mutant p53 respectively. For all analyses
we used a Labinstruments SLT-400 ELISA spectropho-
tometer (Salzburg, Austria) with a 405 nm filter for H.
pylori and a 450 nm filter for p53 [24]. Serum ceruloplas-
min was measured by nephelometry with a Behring
Nephelometer 100 analyzer (Behringwerke AG, Marburg,
Germany).
Statistical analysis
All statistical computations were performed using SPSS
software package (SPSS Version 10.0 for Windows, Inc,
Chicago, IL) [37]. Descriptive statistics were calculated
for each variable (means and confidence intervals). The
statistical significance of the differences between groups
were analyzed by Student's t-test or Mann-Whitney U-
test. Significance of the difference between the seroposi-
tive and seronegative populations in towns with high and
low mortality due to stomach cancer was found for serum
concentration of p53 protein. The possible correlations
between serum ceruloplasmin concentration, H. pylori
IgG antibody level and p53 level. All tests of significance
were 2-tailed, and a P value of 0.05 or less were consid-
ered statistically significant.
Results
Helicobacter H. pylori IgG antibody (Table 1)
In the coastal town of Barbate, 92 of the 308 subjects
(29.87%) were positive for H. pylori IgG antibody, with a
mean value of 242.5 IU/L (95% CI 232-386). Mean value
in negative subjects (n = 216) was 19.4 IU/L (CI 16-24). In
the inland town of Ubrique, 257 of the 319 subjects were
positive (80.56%), with a mean value of 397.3 IU/L (95%
CI 345-405 IU/L). The mean value in negative subjects (n
= 62) was 16.6 IU/L (CI 12-22). The difference in the rate
of seropositivity in the two populations was significant at
p < 0.001.
Mutant p53 genotype (Table 2)
Of the 349 subjects who were seropositive for H. pylori
IgG antibody, 286 (81.94%) had mutant p53, with a mean
value of 0.973 ng/mL (95% CI 0.847-1.098). Of the 278
seronegative subjects, mutant p53 protein was detected
in only 27 (9.71%), with a mean value of 0.239 ng/mL
(95% CI 0.131-0.346). The frequency of quantifiable
mutations was thus significantly higher in subjects who
were seropositive for H. pylori IgG antibody than in sero-
negative subjects (p < 0.001). The mean serum value was
significantly higher in patients with gastric cancer (1.973
ng/mL, 95%, CI 0.895-2.103) than in seropositive subjects
(0.973 ng/mL) or seronegative subjects (0.239 ng/mL)
(both p < 0.001).
Serum ceruloplasmin (Table 2)
Of the 349 subjects who were seropositive for H. pylori
IgG antibody, mean serum concentration of ceruloplas-
min was 477 mg/L (95% CI 435-519). Of the 278 seroneg-
ative subjects, mean concentration was 414 mg/L (95% CI
366-461). Of the 286 subjects who were seropositive for
H. pylori IgG antibody and who also had mutant p53,
mean ceruloplasmin concentration was 486 mg/L (95%
CI 439-532). This was significantly higher than in the 27
subjects who were seronegative for bacterial infection
(420 mg/L, CI 414-433), with t = 2.23 (p < 0.05).
Correlations between variables
We found no significant correlations between p53 and H.
pylori antibody levels (R = 0.038) or between p53 and
ceruloplasmin concentration (R = 0.139) in subjects who
had anti-H. pylori antibodies.
Patients with gastric cancer
Seropositive for H. pylori was detected in 68 of 71 patient
(Table 1). Mean serum levels of mutant p53 in the 71
patients with stomach cancer were 1.973 ng/L (95%,
0.895-2.103). Mean serum concentration of ceruloplas-
min in this group was 763 mg/L (95% CI 703-823). The
mean level of mutant p53 protein in cancer patients was
significantly higher than in healthy individuals who were
seropositive for H. pylori infection (p < 0.001), but higher
than in seronegative subjects (p < 0.01). (Table 2).
Discussion
It is now accepted that H. pylori infection is a risk factor
for stomach cancer. However, the mechanism of carcino-
genesis associated with this bacterial infection in the
stomach remains to be elucidated. The direct effects of H.Lopez-Saez et al. Journal of Experimental & Clinical Cancer Research 2010, 29:65
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pylori are certainly relevant to the induction of atrophic
gastritis and cancer, and a number of virulence factors of
H. pylori m a y  h a v e  a  r o l e  t o  r e g u l a t e  e p i t h e l i a l  c e l l
responses related to inflammation [38,39].
Our results show that among individuals with H. pylori
infection, a higher than normal number also have ele-
vated p53 protein. There appears to be a clear association
between the presence of mutant p53 and seropositivity
for H. pylori; however, prospective studies will be needed
to demonstrate a causal relationship between the two
phenomena. The mean serum level of mutant p53 protein
that we found in persons with H. pylori infection was
higher than the mean value in persons without infection,
and was thus high enough to potentially facilitate the
development of cancer. In those rare cases in which
mutant p53 protein was found in seronegative individu-
als, the mean value was lower than in patients with stom-
ach cancer.
It is a reliable laboratory procedure, since Shim et al,
with the same laboratory procedure of mutant serum p53
measurement have got comparable but higher results in
serum of cases with colorectal carcinoma [40]. The serum
levels of mutant p53 are markers of tissular hyperexpres-
sion of this gene, as has been demostrated Suwa et al, in
patients of pancreatic carcinoma [41]. On the other hand,
Mukarami et al, shown the relationship between H. pylori
infection and a direct sequence analysis of p53 gene
mutation in a biopsy sample of human gastric mucosa,
this finding appears to be involved in the pathway leading
to dysplasia or carcinoma [42].
H. pylori survives in the host causes chronic inflamma-
tion by altering signaling pathways, downregulating
inflammation, and dysregulating host immune responses.
Carcinogenesis in the stomach is a multistage process;
although p53 mutation is an important link in the chain,
perhaps it is a promotion factor and other local initiating
factors are needed for cancer to develop [15]. Our find-
ings emphasize the importance of these additional carci-
nogenic factors, which are not directly related with p53
and were not investigated here. Although p53 mutation is
a necessary factor, it is not in itself sufficient to trigger
stomach cancer.
If a patient is found to be H. pylori positive it is impor-
tant that the infection is eradicated because of the risk of
associated pepti ulcers and gastric cancers. Prospective
studies will disclose the fate of those subjects who are
Table 1: Serum concentration of anti-H. pylori IgG antibodies.
Population N Mean (IU/L) CI
95%
p value
BARBATE 308 -------
H. pylori (+) 92 242.5 232-386 <0.001
H. pylori (-) 216 19.4 16-24
UBRIQUE 319 -------
H. pylori (+) 257 397.3 345-405 <0.001
H. pylori (-) 62 16.6 12-22
GASTRIC CANCER 71 -------
H. pylori (+) 68 400 305-495 <0.001
H. pylori (-) 3 17.4 15-19
CI, confidence interval
Table 2: Serum concentration of mutant p53 protein and ceruloplasmin.
Population N Mutant p53 protein
Mean
(ng/mL)
CI 95% Ceruloplasmin
Mean
(mg/L)
CI 95%
Overall H. pylori positive 349 ----- ----- 477 435-519
HP (+) and p53 positive 286 0.973 0.847-1.098 486 439-532
Overall H. pylori negative 278 ----- ----- 414 366-461
HP (-) and p53 positive 27 0.239 0.131-0.346 420 414-433
Gastric cancer 71 1.973 0.895-2.103 763 703-823
HP, Helicobacter pyloriLopez-Saez et al. Journal of Experimental & Clinical Cancer Research 2010, 29:65
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seropositive for H. pylori and who also develop significant
levels of mutant p53. The results of such studies will
make it easier to determine whether it is worthwhile to
treat H. pylori infection in seropositive but asymptomatic
persons; for now , it seems risky to declare, as do Kon-
turek et al, [43], that prophylactic treatment is not indi-
cated.
The presence of serum mutant p53 in itself provides no
information on whether the mutation was the result of a
genotoxic effect of the bacterium itself, or of a posttran-
scriptional alteration in p53 caused by bacterial toxins.
Although the data from the present study do not shed
light on this issue, the consequences for the p53 molecule
are the same regardless of the mechanism involved.
Shiao et al, has been postulated that chronic atrophic
gastritis, intestinal metaplasia and dysplasia are precan-
cerous stages of stomach tumorigenesis and that muta-
t i o n  o f  p 5 3  g e n e  i s  a n  e a r l y  e v e n t  i n  s t o m a c h
tumorigenesis [44]. Denaturation of the normal protein
due to storage can be ruled out as the cause of the pres-
ence of mutant p53 in our subjects: all blood samples
were processed in an identical manner regardless of H.
pylori status.
H. pylori may exert a mutagenic effect on p53 through
the production of free radicals in the cell. This hypothesis
is supported by the concentrations of serum ceruloplas-
min, an important organic antioxidant: mean concentra-
tion was higher in subjects who were seropositive for H.
pylori and who also had mutant p53, than in subjects who
were negative for both. Other studies have documented
the presence of free radicals in the gastric mucosa of per-
sons with H. pylori infection [45-47].
The contribution of p53 to the subsequent occurrence
of gastric cancer was significant in H. pylori-seropositve
subjects and non in H. pylori-seronegative subjects.
Oxidative damage is well documented in chronic gas-
tric inflammatory diseases [48,49]. Recent published
results showed that mucosal oxidative damage in H.
pylori infection is associated with increased inflamma-
tory cell infiltration, enhanced apoptosis, and cell prolif-
eration, whereas it has been postulated that the
progressive accumulation of oxidative DNA damage in
certain genes, such as p53, may contribute to gastric car-
cinogenesis [26].
Such data suggest that apoptosis may be induced by
both the transcriptional activation of a range of target
genes and also by a range of other events that may pre-
sumably include signal transduction [50].
In summary, our findings suggest that H. pylori infec-
tion contributes to the development of gastric cancer by
elevating the levels of mutant p53. However, although this
may be a necessary promoter in the appearance of cancer,
it is not in itself a risk factor in the absence of a previous
triggering or initiating or mutagenic factor or factors and
the other hand, the presence of anti-H. pylori antibodies
in human sera remains one of the simplest methods of
detecting H. pylori bacteria, and serological methods thus
play an important role in the clinical practice.
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